JP2018512379A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512379A5
JP2018512379A5 JP2017542004A JP2017542004A JP2018512379A5 JP 2018512379 A5 JP2018512379 A5 JP 2018512379A5 JP 2017542004 A JP2017542004 A JP 2017542004A JP 2017542004 A JP2017542004 A JP 2017542004A JP 2018512379 A5 JP2018512379 A5 JP 2018512379A5
Authority
JP
Japan
Prior art keywords
antibody
seq
variable region
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017542004A
Other languages
English (en)
Japanese (ja)
Other versions
JP6895890B2 (ja
JP2018512379A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/017422 external-priority patent/WO2016130726A1/en
Publication of JP2018512379A publication Critical patent/JP2018512379A/ja
Publication of JP2018512379A5 publication Critical patent/JP2018512379A5/ja
Priority to JP2021021535A priority Critical patent/JP7324789B2/ja
Application granted granted Critical
Publication of JP6895890B2 publication Critical patent/JP6895890B2/ja
Priority to JP2023124894A priority patent/JP2023162180A/ja
Priority to JP2025091489A priority patent/JP2025148326A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017542004A 2015-02-10 2016-02-10 ヒト化抗ｍｕｃ１＊ 抗体 Active JP6895890B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021021535A JP7324789B2 (ja) 2015-02-10 2021-02-15 ヒト化抗ｍｕｃ１＊ 抗体
JP2023124894A JP2023162180A (ja) 2015-02-10 2023-07-31 ヒト化抗ｍｕｃ１＊抗体
JP2025091489A JP2025148326A (ja) 2015-02-10 2025-05-30 ヒト化抗ｍｕｃ１＊抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562114526P 2015-02-10 2015-02-10
US62/114,526 2015-02-10
PCT/US2016/017422 WO2016130726A1 (en) 2015-02-10 2016-02-10 Humanized anti-muc1* antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021021535A Division JP7324789B2 (ja) 2015-02-10 2021-02-15 ヒト化抗ｍｕｃ１＊ 抗体

Publications (3)

Publication Number Publication Date
JP2018512379A JP2018512379A (ja) 2018-05-17
JP2018512379A5 true JP2018512379A5 (enExample) 2019-03-14
JP6895890B2 JP6895890B2 (ja) 2021-06-30

Family

ID=56615670

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017542004A Active JP6895890B2 (ja) 2015-02-10 2016-02-10 ヒト化抗ｍｕｃ１＊ 抗体
JP2021021535A Active JP7324789B2 (ja) 2015-02-10 2021-02-15 ヒト化抗ｍｕｃ１＊ 抗体
JP2023124894A Pending JP2023162180A (ja) 2015-02-10 2023-07-31 ヒト化抗ｍｕｃ１＊抗体
JP2025091489A Pending JP2025148326A (ja) 2015-02-10 2025-05-30 ヒト化抗ｍｕｃ１＊抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021021535A Active JP7324789B2 (ja) 2015-02-10 2021-02-15 ヒト化抗ｍｕｃ１＊ 抗体
JP2023124894A Pending JP2023162180A (ja) 2015-02-10 2023-07-31 ヒト化抗ｍｕｃ１＊抗体
JP2025091489A Pending JP2025148326A (ja) 2015-02-10 2025-05-30 ヒト化抗ｍｕｃ１＊抗体

Country Status (8)

Country Link
US (4) US11746159B2 (enExample)
EP (1) EP3256494A4 (enExample)
JP (4) JP6895890B2 (enExample)
CN (2) CN116199790A (enExample)
AU (3) AU2016219350A1 (enExample)
CA (1) CA2976089C (enExample)
IL (1) IL253909B (enExample)
WO (1) WO2016130726A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421819B2 (en) * 2008-10-06 2019-09-24 Minerva Biotechnologies Corporation MUC1* antibodies
SG10201808867PA (en) 2014-04-07 2018-11-29 Minerva Biotechnologies Corp Anti-nme antibody
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CA3039797A1 (en) * 2016-10-11 2018-04-19 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
CN108003237B (zh) * 2016-11-01 2023-03-10 中国科学院广州生物医药与健康研究院 高稳定性的人源化抗人cd3单链抗体及其制法和应用
SG10201912529SA (en) 2016-11-18 2020-02-27 Astellas Pharma Inc Novel anti-human muc1 antibody fab fragment
CN110300603B (zh) 2017-02-14 2023-04-14 亘喜生物科技（上海）有限公司 Cd47-car-t细胞
WO2018205926A1 (zh) * 2017-05-08 2018-11-15 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN111601823B (zh) * 2017-11-07 2024-09-24 德克萨斯大学体系董事会 用car-t或car-nk细胞在癌症治疗中靶向lilrb4
WO2019104306A1 (en) * 2017-11-27 2019-05-31 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and direct use of cleavage enzyme
WO2019165421A1 (en) * 2018-02-26 2019-08-29 Minerva Biotechnologies Corporation Diagnostic methods using anti-muc1* antibodies
US20200405832A1 (en) * 2018-03-09 2020-12-31 Minerva Biotechnologies Corporation Method for anti-muc1* car t cell stimulation
MX2020012351A (es) 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
EP3865154A4 (en) 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
BR112021008486A2 (pt) 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
JP2022527144A (ja) * 2019-01-11 2022-05-31 ミネルヴァ バイオテクノロジーズ コーポレーション 抗可変ｍｕｃ１＊抗体およびその使用
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
KR102834768B1 (ko) * 2019-03-15 2025-07-17 고에키자이단호진 간겐큐카이 항포도플라닌 항체
CA3139319A1 (en) * 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of polypeptides and chimeric antigen receptors via hinge domains
EP3980450A4 (en) * 2019-06-04 2024-06-19 Nkarta, Inc. Combinations of engineered natural killer cells and engineered t cells for immunotherapy
CN114555633A (zh) * 2019-06-26 2022-05-27 约翰霍普金斯大学 用于靶向扩增免疫效应细胞的方法和材料
BR112021026389A2 (pt) * 2019-06-26 2022-04-12 Univ Johns Hopkins Métodos e materiais para expansão direcionada de células t reguladoras
EP3999096A1 (en) * 2019-07-19 2022-05-25 Universiteit Antwerpen Mucin isoforms in diseases characterized by barrier dysfunction
US12049514B2 (en) * 2020-06-08 2024-07-30 Minerva Biotechnologies Corporation Anti-NME antibody and method of treating cancer or cancer metastasis
AU2021286655A1 (en) 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
WO2021263227A2 (en) * 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
JP7719855B2 (ja) * 2020-07-29 2025-08-06 ミネルバ バイオテクノロジーズ コーポレーション 抗可変ｍｕｃ１＊抗体およびその使用
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
MX2024003779A (es) 2021-09-29 2024-04-19 Kisoji Biotechnology Inc Agentes de union dirigidos a celulas tumorales que expresan trop2.
WO2023201234A2 (en) * 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
KR20250024529A (ko) * 2022-05-09 2025-02-18 미네르바 바이오테크놀로지 코포레이션 키메라 항원 수용체 및 il-18 수용체 조성물 및 이의 사용 방법
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2024229126A2 (en) * 2023-05-01 2024-11-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Mutant interleukin 15 expressing immune cells
WO2025250739A1 (en) * 2024-05-31 2025-12-04 Janssen Biotech, Inc. Chimeric antigen receptor with spacer domains derived from human igg

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5108933A (en) 1988-09-16 1992-04-28 Immunicon Corporation Manipulation of colloids for facilitating magnetic separations
JPH02273195A (ja) 1988-11-17 1990-11-07 Univ Melbourne ヒト多型性上皮ムチンと反応するモノクローナル抗体
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
WO1991009134A1 (en) 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5767135A (en) 1995-12-29 1998-06-16 Fernandez-Pol; Jose Alberto Antiviral agent
US6127393A (en) 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
US20020136725A1 (en) 1996-01-17 2002-09-26 Smithkline Beecham Corporation Antithrombotic agents
FR2746016B1 (fr) 1996-03-15 1998-04-17 Combinaisons d'enzymes pour la destruction de cellules proliferatives
ES2287974T3 (es) 1997-02-18 2007-12-16 Canji, Inc. Terapia genica supresora de tumor y quimioterapia combinadas en el tratamiento neoplasmas.
TWI242563B (en) 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
RU2227752C2 (ru) 1998-11-12 2004-04-27 Новолитикс Инк. Способы перекрытия кровотока и композиции для их реализации
EP1137938A4 (en) 1998-12-08 2003-03-19 Smithkline Beecham Corp METHODS FOR DETECTION OF HDPXU17 RECEPTOR AGONISTS AND ANTAGONISTS
WO2000043791A2 (en) 1999-01-25 2000-07-27 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
JP2002535656A (ja) 1999-01-23 2002-10-22 ミナーヴァ・バイオテクノロジーズ・コーポレーション コロイド固定化種と非コロイド構造上の種との相互作用
US20020064528A1 (en) 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
JP2003513920A (ja) 1999-11-12 2003-04-15 ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 細胞内マロニルＣｏＡレベルの増加による癌の治療
CA2421751C (en) 2000-09-11 2014-02-11 Donald W. Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
US20020156112A1 (en) 2000-11-15 2002-10-24 Bamdad R. Shoshana Endostatin-like angiogenesis inhibition
ATE481640T1 (de) 2000-11-27 2010-10-15 Minerva Biotechnologies Corp Diagnostika, drogenscreening und behandlung für krebs
CA2442531A1 (en) 2001-03-29 2002-10-10 Ramot University Authority For Applied Research & Industrial Development Ltd. Peptides and antibodies to muc 1 proteins
US7630836B2 (en) 2001-05-30 2009-12-08 The Kitasato Institute Polynucleotides
ATE469648T1 (de) 2001-09-05 2010-06-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
US20030119834A1 (en) 2001-09-05 2003-06-26 Bamdad Cynthia C. Compositions and methods of treatment of cancer
US6716627B2 (en) 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
CA2482596A1 (en) 2002-04-22 2003-10-30 Dyax Corp. Antibodies specific for mucin polypeptide
WO2003091447A2 (en) * 2002-04-26 2003-11-06 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
EP1536814A4 (en) 2002-07-03 2006-02-15 Immunogen Inc ANTIQUE RPER AGAINST NON-SHED-MUC1 AND MUC16, AND ITS USES
EP2363410B1 (en) 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation Isoforms of MUC1
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20060173171A1 (en) 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2005080432A2 (en) 2004-02-19 2005-09-01 Genentech, Inc. Cdr-repaired antibodies
AU2005280975B2 (en) * 2004-09-06 2009-06-18 Kyowa Hakko Kirin Co., Ltd. Anti-A33 antibody
KR101252306B1 (ko) 2004-10-04 2013-04-08 제넨테크, 인크. 간세포 성장 인자 활성화제의 조정제
CA2610292C (en) 2005-03-30 2015-06-02 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
ES2351057T3 (es) * 2005-07-08 2011-01-31 Pfizer Limited Anticuerpos contra madcam.
US7825092B2 (en) 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
CN101652469B (zh) 2006-12-06 2014-04-16 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
US8420591B2 (en) 2006-12-08 2013-04-16 Dana-Farber Cancer Institute, Inc. MUC1 and galectin-3
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
RU2769948C2 (ru) * 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх CD3-Эпсилон-связывающий домен с межвидовой специфичностью
EP2145901B1 (en) * 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
US10421819B2 (en) 2008-10-06 2019-09-24 Minerva Biotechnologies Corporation MUC1* antibodies
KR20160017117A (ko) 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
JP5773352B2 (ja) * 2008-10-28 2015-09-02 塩野義製薬株式会社 抗ｍｕｃ１抗体
JP5549848B2 (ja) 2008-12-25 2014-07-16 東ソー株式会社 ルテニウム化合物、その製法及びそれを用いた成膜法
EP4043552A1 (en) 2009-06-11 2022-08-17 Minerva Biotechnologies Corporation Methods for culturing stem and progenitor cells
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2012020096A1 (en) * 2010-08-13 2012-02-16 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
CA2852244C (en) 2011-10-17 2023-10-17 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
WO2013157102A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN104995518A (zh) * 2012-07-24 2015-10-21 米纳瓦生物技术公司 Nme变体物种表达和抑制
CA2882222A1 (en) * 2012-08-14 2014-02-20 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
CN112079929A (zh) 2012-11-21 2020-12-15 武汉友芝友生物制药有限公司 双特异性抗体
KR20210082547A (ko) * 2013-02-20 2021-07-05 미네르바 바이오테크놀로지 코포레이션 Ｎｍｅ 저해제 및 ｎｍｅ 저해제의 사용 방법
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
ES2794088T3 (es) * 2014-01-29 2020-11-17 Dana Farber Cancer Inst Inc Anticuerpos contra el dominio extracelular de MUC1-C (MUC1-C/ECD)
CN103880956B (zh) * 2014-03-10 2015-12-30 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区
SG10201808867PA (en) 2014-04-07 2018-11-29 Minerva Biotechnologies Corp Anti-nme antibody
EP3137498A1 (en) * 2014-05-02 2017-03-08 Cellectis Cs1 specific multi-chain chimeric antigen receptor
US10865243B2 (en) 2014-07-16 2020-12-15 Hinrich Abken Chimeric antigen receptor and its use
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2017139906A1 (zh) 2016-02-17 2017-08-24 王守国 一种等离子体加热器
CA3039797A1 (en) * 2016-10-11 2018-04-19 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and use of cleavage enzyme
WO2019104306A1 (en) * 2017-11-27 2019-05-31 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and direct use of cleavage enzyme

Similar Documents

Publication Publication Date Title
JP2018512379A5 (enExample)
Kaplon et al. Antibodies to watch in 2022
JP2021191763A5 (enExample)
CN115052893A (zh) 抗tigit抗体和使用方法
JP2019535670A5 (enExample)
JP2019536470A5 (enExample)
HRP20240959T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1
JP2017535257A5 (enExample)
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
JP2018520993A5 (enExample)
JP2015163068A5 (enExample)
RU2017102514A (ru) Гуманизированные анти-тау-антитела
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2016533763A5 (ja) ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物
CN110799543A (zh) 肝细胞癌的免疫治疗
JP2013198490A5 (enExample)
JP2017149720A5 (enExample)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2017500057A5 (enExample)
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use
JP2020514277A5 (enExample)
JP2014205674A5 (enExample)
JP2016505546A5 (enExample)
JP2017529324A5 (enExample)
JP2015509960A5 (enExample)